Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Working Capital Changes (2016 - 2025)

Vanda Pharmaceuticals' Other Working Capital Changes history spans 16 years, with the latest figure at $5.9 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 63.43% year-over-year to $5.9 million; the TTM value through Dec 2025 reached $12.1 million, up 77.04%, while the annual FY2025 figure was $12.1 million, 77.04% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was $5.9 million at Vanda Pharmaceuticals, up from -$703000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $13.4 million in Q1 2022 and bottomed at -$11.3 million in Q1 2023.
  • The 5-year median for Other Working Capital Changes is $1.3 million (2021), against an average of $887150.0.
  • The largest YoY upside for Other Working Capital Changes was 26820.0% in 2022 against a maximum downside of 398.11% in 2022.
  • A 5-year view of Other Working Capital Changes shows it stood at -$1.7 million in 2021, then tumbled by 104.57% to -$3.4 million in 2022, then tumbled by 108.59% to -$7.2 million in 2023, then skyrocketed by 150.58% to $3.6 million in 2024, then soared by 63.43% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Other Working Capital Changes are $5.9 million (Q4 2025), -$703000.0 (Q3 2025), and $1.4 million (Q2 2025).